LTGO (Latigo Biotherapeutics) Preferred Stock: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTGO Latigo Biotherapeutics Inc LTGO
8 GF Score
Price $18.12
View Full Analysis

What is Latigo Biotherapeutics Preferred Stock?

Latigo Biotherapeutics LTGO -0.71% 8 Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates LTGO with a GF Score™ of 8/100.

Preferred stock is a special equity security that has properties of both equity and debt. Latigo Biotherapeutics's preferred stock for the quarter that ended in Dec. 2025 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Latigo Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $-69.31 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Latigo Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Latigo Biotherapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $.


Latigo Biotherapeutics  (NAS:LTGO) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Latigo Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2025 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Latigo Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2025 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Latigo Biotherapeutics's Earnings per Share (Diluted) (EPS) for the six months ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Latigo Biotherapeutics Preferred Stock Related Terms


Latigo Biotherapeutics Preferred Stock Historical Data

* Premium members only.

The historical data trend for Latigo Biotherapeutics's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Latigo Biotherapeutics Preferred Stock Chart

Latigo Biotherapeutics Annual Data
Trend Dec24 Dec25
Preferred Stock
0.00 0.00

Latigo Biotherapeutics Semi-Annual Data
Dec24 Dec25
Preferred Stock 0.00 0.00
LTGO
8GF Score
Latigo Biotherapeutics Inc LTGO
Preferred Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Latigo Biotherapeutics Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of $0.00 Mil mean?
Latigo Biotherapeutics (LTGO) has a Preferred Stock of $0.00 Mil as of Dec. 2025. Preferred Stock represents the par value of a company's preferred shares. View historical data on Latigo Biotherapeutics and its competitors.
Is Latigo Biotherapeutics' Preferred Stock too high?
Latigo Biotherapeutics' current Preferred Stock is $0.00 Mil. Overall, Latigo Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Latigo Biotherapeutics' Preferred Stock compare to ?
Latigo Biotherapeutics' Preferred Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Biotechnology company?
A good Preferred Stock depends on the Biotechnology industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Latigo Biotherapeutics and its competitors. Latigo Biotherapeutics's current Preferred Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Latigo Biotherapeutics stock overvalued right now?
Latigo Biotherapeutics (LTGO) has a current Preferred Stock of $0.00 Mil. The current Preferred Stock is $0.00 Mil. Latigo Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Latigo Biotherapeutics (LTGO), the current Preferred Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Latigo Biotherapeutics Business Description

Comparable Companies
Address 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA, USA, 91320
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
8GF Score

Get the complete analysis for LTGO

Preferred Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.12
Price